MARKET

AGTC

AGTC

AGTC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.370
+0.170
+5.31%
After Hours: 3.370 0 0.00% 18:25 04/08 EDT
OPEN
3.250
PREV CLOSE
3.200
HIGH
3.430
LOW
3.220
VOLUME
68.79K
TURNOVER
--
52 WEEK HIGH
10.42
52 WEEK LOW
2.290
MARKET CAP
83.30M
P/E (TTM)
-3.1789
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AGTC stock price target is 15.64 with a high estimate of 25.00 and a low estimate of 7.50.

EPS

AGTC News

More
  • Applied Genetic Technologies (AGTC) Investor Presentation - Slideshow
  • Seeking Alpha - Article · 1d ago
  • All You Need to Know About Applied Genetic Technologies (AGTC) Rating Upgrade to Buy
  • Zacks · 03/24 17:00
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36
  • AGTC Announces Completion of Enrollment in All Adult Dose Groups of its Ongoing Phase 1/2 Clinical Trials in Patients with Achromatopsia
  • GlobeNewswire · 03/16 12:00

Industry

Biotechnology & Medical Research
+3.08%
Pharmaceuticals & Medical Research
+2.83%

Hot Stocks

Symbol
Price
%Change

About AGTC

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).
More

Webull offers kinds of Applied Genetic Technologies Corp stock information, including NASDAQ:AGTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGTC stock news, and many more online research tools to help you make informed decisions.